key: cord-0819867-tqxz2rz2
authors: de Miranda Santos, Isabel Kinney Ferreira; de Barros Cardoso, Cristina Ribeiro
title: Commentary on “Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al.
date: 2020-10-27
journal: Clin Immunol
DOI: 10.1016/j.clim.2020.108618
sha: dbb019028fa8a69db9c9498ad21249f84e30e33a
doc_id: 819867
cord_uid: tqxz2rz2

nan

Both schizophrenia [5] and delirium [6] , including the delirium of critically ill COVID-19 patients [7] have recently been shown to be heritable conditions. While changes in mental functions in psychiatric diseases such as schizophrenia do not, by definition, meet the criteria for delirium, psychotic symptoms are components of delirium. Indeed, Charlton and Kavanau [8] have proposed a model that integrates delirium and psychosis and that also places delirium as a spectrum of manifestations in psychiatric disease.

Importantly, through a meta-analysis of genome-wide association studies on schizophrenia, Sekar and colleagues found an association between phenotype, i.e., schizophrenia or health, and alleles of the complement component 4 (C4) genes [9] . Also importantly, these alleles generate levels of C4 expression in the brain that vary widely and are associated with phenotype.

Furthermore, those authors also showed that C4 protein localized to neuronal synapses, dendrites, axons, and cell bodies. Of even further interest is the fact the genetic variants of C4 explain sex biases for many diseases in men [10] , of which COVID-19 is probably the most recent and currently notorious example.

It is therefore reasonable to hypothesize that complement may participate in the generation of delirium that frequently occurs in critically ill patients, including severe COVID-19. Mastellos and colleagues did not address delirium in the report involving their cohorts and it would be interesting to make this observation in future clinical trials of the C5-targeting monoclonal antibody eculizumab and of the compstatin-based C3-targeted drug candidate AMY-101, both being components that are downstream from C4 in the complement cascade.

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement

Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit

Delirium Epidemiology in Critical Care Study Group. Delirium epidemiology in critical care (DECCA): an international study

The genetics of schizophrenia: a current, genetic-epidemiologic perspective

Delirium -biomarkers and genetic variance

Self-reported symptoms of COVID-19 including symptoms most predictive of SARS-CoV-2 infection, are heritable. medRxiv

Delirium and psychotic symptoms -an integrative model

Schizophrenia risk from complex variation of complement component 4

Complement genes contribute sex-biased vulnerability in diverse disorders

The authors acknowledge funding for their COVID-19 studies by the Fundação de Amparo à Pesquisa do Estado de São Paulo -FAPESP, grant numbers 2020/09093-5 and 2020/05270-0.